Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus and Diabetes After Total Pancreatectomy

This research is being done to better understand how insulin effects muscle, blood, and the body in people with Type 1 Diabetes.

Start Date01 Dec 2025

Sponsor / Collaborator

Mayo Clinic

NCT06955130

/ Not yet recruitingPhase 1IIT

Lactate and Glycerol Contribution to Gluconeogenesis

A major cause of increased blood glucose levels in type 2 diabetes (T2D) is increased hepatic gluconeogenesis (GNG), as the liver converts various substrates into glucose. Two of these substrates include glycerol, a molecule from fat, and lactate, a molecule that circulates in the blood. Our previously collected data suggest that glycerol's role in this process has been underestimated, so the investigators will directly compare the carbon contribution of glycerol and lactate to new glucose production under fasting conditions in patients with and without T2D. The investigators will also assess how glucagon, a hormone that raises blood glucose levels, impacts the conversion of glycerol and lactate to glucose. Enrolled participants will undergo three separate isotope tracer infusions with serial blood collections for liquid chromatography-mass spectrometry analysis. This research could identify new therapeutic drug targets that can lower blood glucose levels more directly and effectively.

Start Date01 Aug 2025

Sponsor / Collaborator

Rutgers State University of New Jersey

NCT07008456

/ Not yet recruitingPhase 2

A Phase II Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations (APHD 012 and APHD 002) Combined With a Gel Composition, Compared With Two Different Doses of the Placebo Beads Formulations (APHP 012 and APHP 002) Combined With a Gel Composition in Obese Subjects With Weight Related Comorbidities

The goal of this randomized, double-blind, placebo-controlled, phase IIa study is to demonstrate superiority on body weight reduction of two different doses of twice daily distal jejunal-release dextrose beads formulations (APHD 012 and APHD 002) combined with a gel composition, compared with two different doses of the placebo beads formulations (APHP 012 and APHD 002) combined with a gel composition in obese subjects with weight related comorbidities.

Start Date01 Jul 2025

Sponsor / Collaborator-

100 Clinical Results associated with Dextrose

100 Translational Medicine associated with Dextrose

100 Patents (Medical) associated with Dextrose

5,180

Literatures (Medical) associated with Dextrose

31 Dec 2025·Journal of the International Society of Sports Nutrition

Effect of different sports drink compositions on endurance performance and substrate oxidation: a randomized, double-blind, placebo-controlled crossover study in trained athletes

Article

Author: Ketelhut, Sascha ; Moehle, Martin ; Hottenrott, Laura

BACKGROUND:

The consumption of sports drinks before, during, and after endurance exercise is a common practice among athletes. These drinks typically contain a variety of components, each of which has been shown to offer individual benefits. However, the combined effects of these components, as formulated in many sports drinks, have not been thoroughly investigated. This study aims to evaluate the impact of typical sports drink components on endurance performance, perceived exertion, and carbohydrate and fat metabolism, using a sequential additive design.

METHODS:

Twelve healthy, trained endurance athletes aged 20 to 35 years participated in a randomized, double-blind, placebo-controlled study. The study involved a baseline assessment and four exercise protocols, each separated by a 7-day washout period. During each exercise protocol, participants cycled for 40 minutes at 80% of their previously determined peak oxygen uptake , followed by an incremental protocol performed to voluntary exhaustion. Participants were randomly assigned to ingest one of four 300 ml solutions 60 and 30 minutes before each exercise protocol: solution A (placebo mineral water), solution B (dextrose and sodium), solution C (solution B + beetroot extract), or solution D (solution C + arginine and L-citrulline). Ventilation and heart rate were continuously monitored before and throughout the exercise. Lactate and glucose levels were measured at specific time points before and during the exercise, while ratings of perceived exertion were recorded every 10 minutes. Power output was continuously tracked throughout the exercise protocol. Body weight was assessed both before and after each exercise session.

RESULTS:

There were no significant differences between the four solutions in terms of time to exhaustion (p = .703), power output (p = .822), peak oxygen uptake (p = 990), maximum lactate concentration (p = .720), and maximum heart rate (p = .884). During the exercise, no significant differences were observed in lactate and glucose concentrations, heart rate, or ventilatory parameters (ps > .050). However, significant differences (p < .001) in blood glucose concentrations were noted at rest and during the warm-up phase.

CONCLUSIONS:

The effect of the tested sports drink compositions on performance during the selected exercise protocol to voluntary exhaustion appears minimal. This study found no significant differences between the solutions and the placebo. Thus, it can be concluded that consuming a dextrose-based solution before exercise did not offer any performance advantage over water. The additional substances included in solutions B, C, and D did not influence performance, carbohydrate metabolism, or fat metabolism during the exercise.

15 Aug 2025·JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE

Pseudovitamin B₁₂ producing Loigolactobacillus coryniformis enhances soy milk fermentation by Lactobacillus delbrueckii subsp. bulgaricus

Article

Author: Tsuda, Harutoshi ; Iwai, Kunihisa ; Hayashizaki, Natsuki

Abstract:

BACKGROUND:

Fermenting soy milk with lactic acid bacteria is challenging. Generally, carbohydrates are added to enhance the acid production in soy milk. However, the yoghurt starter Lactobacillus delbrueckii subsp. bulgaricus did not succeed in fermenting soy milk supplemented with carbohydrates. If this yoghurt starter could be used with soy milk, it is expected that it would produce a yoghurt‐like flavour, making soy yoghurt more appealing. In this study, we aimed to ferment soy milk using Lb. delbrueckii subsp. bulgaricus and pseudovitamin B12‐producing lactic acid bacteria.

RESULTS:

Loigolactobacillus coryniformis SAB01 was found to produce corrinoid in soy milk, with the highest production being observed at 20 °C. The produced corrinoid was identified as pseudovitamin B12 using ultra‐performance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry. Another bacterial strain, Lb. delbrueckii subsp. bulgaricus NBRC 13953, was examined for its ability to produce lactic acid in soy milk. Compared with soy milk supplemented with glucose or cyanocobalamin alone, the highest lactic acid production was observed in soy milk supplemented with both glucose and cyanocobalamin. These findings indicate that the combined addition of glucose and cyanocobalamin enhances lactic acid production by strain NBRC 13953 in soy milk. We accordingly examined lactic acid production in soy milk inoculated with strains SAB01 and NBRC 13953, and found that a substantial quantity of lactic acid was produced when glucose was added to soy milk.

CONCLUSIONS:

Our findings in this study indicate that the growth of Lb. delbrueckii subsp. bulgaricus NBRC 13953 was promoted by the pseudovitamin B12 produced by Loigolactobacillus coryniformis SAB01, thereby suggesting a novel symbiotic relationship between these two lactic acid bacteria in soy milk. © 2025 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.

01 Aug 2025·BIORESOURCE TECHNOLOGY

Carbon distribution and metabolism mechanism of a novel mixotrophic Chlorella in municipal wastewater

Article

Author: Sun, Dezhi ; Zhang, Yuewen ; Wang, Xiaoyan ; Hong, Yu

Conventional wastewater treatment technologies primarily convert complex organic matter into dissolved inorganic carbon (DIC) and a more difficult gaseous state CO₂. Most microalgae species can photosynthetically assimilate above inorganic carbon, but their heterotrophic metabolic processes often dominate in glucose-mediated mixotrophy. Herein, we investigated the carbon-fixing metabolic pathways of Chlorella sp. MIHQ61 in municipal wastewater containing complex carbon sources. The total carbon removal (73.0 %) peaked on the 6th day, and DIC removal exceeded 50.0 % as the carbon migrating amount from municipal wastewater into the microalgal cells peaked. The glucose and NaHCO₃ combination promoted both autotrophic and heterotrophic metabolism. Headspace CO₂ emission, enzyme activity and central carbon metabolism results implied heterotrophic metabolism occurred more actively in the early stage and autotrophic metabolism dominated late stage. Redefined mixotrophic carbon allocation by revealing time-dependent autotrophic/heterotrophic interplay. Carbon distribution and mixotrophic mechanism provided new thinking on how to utilize microalgae and wastewater resource.

News (Medical) associated with Dextrose

11 Jun 2025

·www.fiercebiotech.com

Tandem Diabetes Care to link insulin pump with Abbott\'s upcoming glucose-ketone wearable

Tandem said the agreement with Abbott includes plans to offer an integrated diabetes solution. \n Tandem Diabetes Care announced plans to link its automated insulin delivery systems with an upcoming wearable monitor from Abbott that aims to measure blood glucose as well as ketone levels.The dual sensor, which has been under development for years, is designed to help users spot the early signs of diabetic ketoacidosis, a life-threatening condition that can develop in some people with Type 1 diabetes. “Integrating our advanced insulin delivery systems with Abbott’s future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes,” Tandem’s president and CEO, John Sheridan, said in a statement. Tandem also said the agreement includes plans to commercialize an integrated diabetes solution. Abbott has said that its new sensor will be built on its FreeStyle Libre 3 continuous glucose monitoring platform and will be the same size, and that it will also work with the company’s suite of digital tools. The system previously received a breakthrough designation from the FDA in 2022. And Tandem isn’t the only company waiting in line. Last month, the insulin delivery newcomer Sequel Med Tech said its twiist pump would also connect with Abbott’s planned device, once it receives regulatory clearance and is made available in the U.S.Sequel, a recently named Fierce Medtech Fierce 15 winner, is now in the process of rolling out its twiist automated insulin delivery system; the company previously announced that it would work with Abbott’s current FreeStyle Libre 3 Plus, as well as Senseonics’ 365-day Eversense CGM.

$Tandem Diabetes Care to link insulin pump with Abbott\'s upcoming glucose-ketone wearable$

Breakthrough Therapy

10 Jun 2025

·www.businesswire.com

Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. "Integrating our advanced insulin delivery systems with Abbott’s future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes," said John Sheridan, president and chief executive officer. "We are excited to continue our partnership with Abbott and look forward to working with them to bring this new integration to customers in the future." About Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com. Follow @TandemDiabetes on Facebook, Instagram, LinkedIn, TikTok, and X. Forward-looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, development plans to integrate Tandem insulin delivery systems with Abbott dual glucose and ketone sensing technology. These forward-looking statements are subject to numerous risks and uncertainties, including risks, for example, that technical challenges, clinical or regulatory hurdles or other factors may prevent or delay integration, as well as other risks identified in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents that we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors. ©2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.

22 May 2025

·www.globenewswire.com

Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott’s Future Dual Glucose-Ketone Sensor

Integration of Abbott’s glucose-ketone sensor with the twiist™ AID System aims to enhance early identification of rising ketones to detect the risk of diabetic ketoacidosis (DKA)1MANCHESTER, N.H., May 22, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies today announced a commercial development agreement for future integration of Sequel’s twiist™ Automated Insulin Delivery (AID) System powered by Tidepool, with Abbott’s glucose-ketone sensor, currently under development. The agreement aims to improve outcomes for people with type 1 diabetes by adding ketone sensing capabilities to a Libre glucose sensor in combination with the twiist AID System to enable earlier detection of rising ketones. Regular measurement of ketones has been shown to reduce the risk of diabetic ketoacidosis in people living with type 1 diabetes2. Sequel’s expanded integration with Abbott’s sensor underscores the company’s commitment to delivering more choice, flexibility and confidence to people managing type 1 diabetes. “By integrating the twiist AID System with Abbott’s future glucose-ketone sensor, Sequel will be able to offer people with diabetes greater choice and the potential for improved outcomes in managing their care. twiist was designed to rapidly identify interruptions in insulin delivery, so combining this with early identification of rising ketones could help people living with diabetes react more quickly and more confidently,” said Sequel CEO and Co-Founder Alan Lotvin, M.D. “Through this collaboration, we are redefining what people living with diabetes can expect from an AID system.” People living with type 1 diabetes who use twiist will be able to select from compatible CGM systems, including Abbott’s FreeStyle Libre® 3 Plus sensor and, in the future, the Senseonics Eversense 365 to best suit their individual needs for managing diabetes. Abbott’s glucose-ketone sensor will be added in the future once the product is cleared for use and available in the U.S. The twiist AID System features proprietary iiSure™ Technology, which directly measures the volume of insulin delivered with each micro-dose. It includes four checkpoints that measure the insulin quantity delivered and enables the system to alert users to blockages up to nine times faster than competing AID systems3. Cleared for people ages six and up with type 1 diabetes, the twiist AID System offers the capability and flexibility to address each person’s individual dosing needs. The twiist Loop algorithm, based on Tidepool Loop, an intuitive and smart technology designed by people with diabetes for people with diabetes, allows the system to automatically adjust basal insulin delivery based on real-time sensor readings and predicted glucose levels. You can learn more about twiist, set to be commercially available in Q2 2025, and sign up for the latest updates on availability at www.twiist.com. About Sequel Med Tech Headquartered in Manchester, N.H., Sequel Med Tech, LLC is developing the next generation of transformative drug-delivery advancements. Sequel’s approach is to look at disease management holistically to advance systems that make living with disease simpler and easier for all. Its FDA-cleared innovation, the twiist® Automated Insulin Delivery (AID) system, integrates novel technologies to reimagine insulin delivery and sets a new standard for drug delivery. Co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare visionary Alan Lotvin, MD. Sequel is bringing the latest developments in science and technology to help drive more accessible drug delivery. For more information, visit sequelmedtech.com and twiist.com. Sequel Media ContactGreta GustafsonHighwire PRsequel.med.tech@highwirepr.com Cherubini, V., Grimsmann, J.M., Åkesson, K. et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia 63, 1530–1541 (2020).Misra S, Oliver NS. Utility of ketone measurement in the prevention, diagnosis and management of diabetic ketoacidosis. Diabet Med. 2015;32(1):14-23. doi:10.1111/dme.12604.Calculation based on a comparison of the following IFUs. The following reported 1 U/hr basal rate: Sequel Med Tech - twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide ; Insulet - Omnipod 5 Automated Insulin Delivery System User Guide ; Medtronic - MiniMed 780G system User Guide ; Beta Bionics - iLet Bionic Pancreas System User Guide. The following reported 2 U/hr basal rate: Tandem Diabetes Care - t:slim X2 Insulin Pump User Guide ; Tandem Diabetes Care - Tandem Mobi System User Guide.

License out/in

100 Deals associated with Dextrose

External Link

KEGG	Wiki	ATC	Drug Bank
D02325	Dextrose	-	DB09341

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Water-Electrolyte Imbalance	United States	Baxter Healthcare Corp.	25 Jan 1971

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 2	Slovakia	-	31 Mar 2023
Prediabetic State	Phase 2	Slovakia	-	31 Mar 2023
Obesity	Phase 2	Georgia	-	01 Nov 2022
Obesity	Phase 2	Germany	-	01 Nov 2022
Obesity	Phase 2	Puerto Rico	-	01 Nov 2022
Glycogen Storage Disease	IND Approval	China	Beijing CoSci Med-Tech Co., Ltd.	20 Jan 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05803772 (GlobeNewswire) Manual	Phase 2	Prediabetic State	-	APHD-012	hfyqyajopt(hlqefugihu) = In a group of healthy, prediabetic and diabetic patients, APHD-012 (6 weeks treatment) reduced OGTT blood glucose levels at 120 minutes post-challenge from 9.00.6 to 7.90.6 mmol/L (n=23, p=0.01); placebo treatment in the same patients had no significant effect (8.80.4 mmol/L versus 8.50.6 mmol/L; p=0.33) tawatgnjqr (onxwbtwkwg ) View more	Positive	20 Jun 2024
				placebo
ATS2024	Not Applicable	syndrome; salt-losing, adrenogenital syndrome	-	Scheduled insulin therapy	oumulypbvs(nxrirudkqa) = revealed central pontine T2 prolongation suggesting osmotic demyelination syndrome with no other abnormalities hegzadaags (ksxhsffpya ) View more	-	19 May 2024
NCT01369147 (CTgov)	Phase 2	Critical Illness	12	Enteral feeding+Propofol+Clevidipine+Dextrose (Parenteral Nutrition Energy Dose at 0.6 x Measured REE)	hrtnpeaqth = mjywoouvyl zotzjuowty (dczfzcokmp, tlgvhlvobq - zwdbiamwpa) View more	-	10 Jun 2022
				Enteral feeding+Propofol+Clevidipine+Dextrose (Parenteral Nutrition Energy Dose at 1.0 x Measured REE)	hrtnpeaqth = ptzxoiqnkq zotzjuowty (dczfzcokmp, sbidkpkabp - dgzztxcaks) View more
ATS2022	Not Applicable	Acidosis, Lactic	-	Diazoxide	kttndbqsua(dupjhsmund) = severe lactic acidosis following high dextrose infusion in a patient with an insulinoma qeotohypbp (eiwkymxkex )	-	15 May 2022
				Dextrose infusion
ERA2022	Not Applicable	-	108	4.25% Peritoneal Equilibration Test (PET-4.25%)	euxmbodqgl(raoqjixjlp) = zharkhnsyq bfoofwiwkj (fdbftmewsl, 0.27) View more	Positive	03 May 2022
ADA2021	Not Applicable	Hypoglycemia	10	Glucose	zpsfimhaqf(fzsdrftgtn) = xfazutytfq dhehxlnamw (tcluwxhbwd ) View more	-	01 Jun 2021
ENDO2021	Not Applicable	Congenital Hyperinsulinism PIK3CA gene	-	Diazoxide	pmdymaiyuz(dwsknlakql) = hcbsktpupy nczrbiupdz (akozwffpyz ) View more	-	03 May 2021
				Octreotide	pmdymaiyuz(dwsknlakql) = uzuikzsyao nczrbiupdz (akozwffpyz ) View more
GLOW (NAASO2020)	Not Applicable	fasting plasma glucose \| fasting plasma insulin \| HOMA-IR ... View more	436	Gelesis100	mficywaxqz(hbqpcgofqx): mean difference = 0.1 (95% CI, 0.02 - 0.17), P-Value = 0.011	-	04 Nov 2020
				Placebo
ASN2019	Not Applicable	Hyperkalemia	142	Intravenous Insulin and Dextrose 50%	bwxukxqafe(cwacqpbujs) = kaijmhaofa omvstvkwbp (zrppbhjwrq, 1.67 - 16.0) View more	Positive	05 Nov 2019
ERA2019	Not Applicable	HOMA-IR \| BMI	35	intravenous glucose injection (Diabetic patients)	ateimuevln(drslsnydov) = csuwirujfe zanmltxxfz (lpwwykthhg )	Positive	13 Jun 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis